Conditions: Breast Cancer
Keywords: Breast cancer letrozole anastrozole adjuvant postmenopausal FACE
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 4172
Healthy volunteers: no

Brief summary:
Eligible patients will be post-menopausal hormone receptor- and lymph node-positive females who recently underwent primary surgery for breast cancer. Patients will be randomized to letrozole (2.5 mg per day for 5 years) vs anastrozole (1 mg per day for 5 years). Follow up will occur for 5 years after the completion of enrollment for survival and disease status updates.

Detailed description:

Arms:
arm 1: 2.5 mg by mouth (p.o.) once daily arm 2: 1 mg p.o. once daily

Interventions: intervention 1: Letrozole intervention 2: Anastrozole
Intervention descriptions: intervention 1: 2.5 mg tablets intervention 2: 1 mg tablets

Protocol document: